» Articles » PMID: 35242360

Intra-host Analysis of Hepaciviral Glycoprotein Evolution Reveals Signatures Associated with Viral Persistence and Clearance

Abstract

Even 30 years after the discovery of the hepatitis C virus (HCV) in humans there is still no vaccine available. Reasons for this include the high mutation rate of HCV, which allows the virus to escape immune recognition and the absence of an immunocompetent animal model for vaccine development. Phylogenetically distinct hepaciviruses (genus , family ) have been isolated from diverse species, each with a narrow host range: the equine hepacivirus (EqHV) is the closest known relative of HCV. In this study, we used amplicon-based deep-sequencing to investigate the viral intra-host population composition of the genomic regions encoding the surface glycoproteins E1 and E2. Patterns of E1E2 substitutional evolution were compared in longitudinally sampled EqHV-positive sera of naturally and experimentally infected horses and HCV-positive patients. Intra-host virus diversity was higher in chronically than in acutely infected horses, a pattern which was similar in the HCV-infected patients. However, overall glycoprotein variability was higher in HCV compared to EqHV. Additionally, selection pressure in HCV populations was higher, especially within the N-terminal region of E2, corresponding to the hypervariable region 1 (HVR1) in HCV. An alignment of glycoprotein sequences from diverse hepaciviruses identified the HVR1 as a unique characteristic of HCV: hepaciviruses from non-human species lack this region. Together, these data indicate that EqHV infection of horses could represent a powerful surrogate animal model to gain insights into hepaciviral evolution and HCVs HVR1-mediated immune evasion strategy.

Citing Articles

Dynamic evolution of the sofosbuvir-associated variant A1343V in HEV-infected patients under concomitant sofosbuvir-ribavirin treatment.

Gomer A, Dinkelborg K, Klohn M, Jagst M, Wissing M, Frericks N JHEP Rep. 2024; 6(3):100989.

PMID: 38434938 PMC: 10906529. DOI: 10.1016/j.jhepr.2023.100989.


A panel of hepatitis C virus glycoproteins for the characterization of antibody responses using antibodies with diverse recognition and neutralization patterns.

Chumbe A, Grobben M, Capella-Pujol J, Koekkoek S, Zon I, Slamanig S Virus Res. 2024; 341:199308.

PMID: 38171391 PMC: 10821612. DOI: 10.1016/j.virusres.2024.199308.


Dose-Dependent Hepacivirus Infection Reveals Linkage between Infectious Dose and Immune Response.

Gomer A, Delarocque J, Puff C, Nocke M, Reinecke B, Baumgartner W Microbiol Spectr. 2022; 10(5):e0168622.

PMID: 35993785 PMC: 9602444. DOI: 10.1128/spectrum.01686-22.


An Equine Model for Vaccination against a Hepacivirus: Insights into Host Responses to E2 Recombinant Protein Vaccination and Subsequent Equine Hepacivirus Inoculation.

Badenhorst M, Saalmuller A, Daly J, Ertl R, Stadler M, Puff C Viruses. 2022; 14(7).

PMID: 35891381 PMC: 9318657. DOI: 10.3390/v14071401.


Experimental cross-species infection of donkeys with equine hepacivirus and analysis of host immune signatures.

Gomer A, Puff C, Reinecke B, Bracht S, Conze M, Baumgartner W One Health Outlook. 2022; 4(1):9.

PMID: 35527255 PMC: 9082851. DOI: 10.1186/s42522-022-00065-y.

References
1.
Zibert A, Meisel H, Kraas W, Schulz A, Jung G, Roggendorf M . Early antibody response against hypervariable region 1 is associated with acute self-limiting infections of hepatitis C virus. Hepatology. 1997; 25(5):1245-9. DOI: 10.1002/hep.510250530. View

2.
Tanaka T, Kasai H, Yamashita A, Okuyama-Dobashi K, Yasumoto J, Maekawa S . Hallmarks of hepatitis C virus in equine hepacivirus. J Virol. 2014; 88(22):13352-66. PMC: 4249100. DOI: 10.1128/JVI.02280-14. View

3.
Baechlein C, Fischer N, Grundhoff A, Alawi M, Indenbirken D, Postel A . Identification of a Novel Hepacivirus in Domestic Cattle from Germany. J Virol. 2015; 89(14):7007-15. PMC: 4473572. DOI: 10.1128/JVI.00534-15. View

4.
Joseph S, Swanstrom R, Kashuba A, Cohen M . Bottlenecks in HIV-1 transmission: insights from the study of founder viruses. Nat Rev Microbiol. 2015; 13(7):414-25. PMC: 4793885. DOI: 10.1038/nrmicro3471. View

5.
Guglietta S, Garbuglia A, Pacciani V, Scotta C, Perrone M, Laurenti L . Positive selection of cytotoxic T lymphocyte escape variants during acute hepatitis C virus infection. Eur J Immunol. 2005; 35(9):2627-37. DOI: 10.1002/eji.200526067. View